Stelis

Pharmaceutical Contract Manufacturing Market Size to Hit USD 140 billion by 2030 Say, Roots Analysis

Retrieved on: 
Monday, January 15, 2024
Warburg Pincus, HUF, Blister, Overalls, Route of administration, API, OneSource, Advent International, Investment, Acquisition, Drug development, Stelis, FDF, Baxter International, Organization, CDMO, CMOS, Egis, Clinical trial, Growth, Fine chemical

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030). 

Key Points: 
  • The global pharmaceutical contract manufacturing market faces challenges in the form of high initial investment costs for equipment and facilities.
  • Commercial segment will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 81% by 2030.
  • Based on the type of end users, the pharmaceutical contract manufacturing market is segmented into small, mid-sized, and large pharmaceutical companies.
  • Asia-Pacific will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 37% of the market share by 2030.

Pharmaceutical Contract Manufacturing Market Size to Hit USD 140 billion by 2030 Say, Roots Analysis

Retrieved on: 
Monday, January 15, 2024
Blister, Overalls, Route of administration, API, OneSource, Advent International, Investment, Acquisition, Medication, Drug development, Stelis, FDF, Baxter International, Organization, CDMO, CMOS, Clinical trial, Growth, Fine chemical

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030). 

Key Points: 
  • The global pharmaceutical contract manufacturing market faces challenges in the form of high initial investment costs for equipment and facilities.
  • Commercial segment will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 81% by 2030.
  • Based on the type of end users, the pharmaceutical contract manufacturing market is segmented into small, mid-sized, and large pharmaceutical companies.
  • Asia-Pacific will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 37% of the market share by 2030.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Retrieved on: 
Friday, June 24, 2022
COVID-19, Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Process, Research, Immortalised cell line, STAR, COVID-19, Delta, Company, Longevity, Volunteering, Serum, Seroconversion, ANVISA, Vaccine, EUA, Stelis, Efficiency, WHO, RNA transfection, Fahrenheit, BSE, Population, Immunization, UK, Omicron, GMP, PD, National Stock Exchange of India, Merck, USFDA, Martek Biosciences Corporation, Insulin glargine, Insulin, Global, Diabetes, CEO, DPH, Peptide, Insulin lispro, Immunoglobulin G, Insulin aspart, Partnership, Technology, Temperature, Merck & Co., Leadership, Stride, SmartCell Technology, National Stock Exchange, Porantha Veeda Puguntha Veeda, CDMO, COVID-19 vaccine, Maintenance, Developing country, Safety, Immunity, Pharmaceutical industry, Fine chemical, Phase

The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).

Key Points: 
  • The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).
  • Akston and Strides group have already signed a licensing, manufacturing, and commercialization agreement to launch this vaccine worldwide as AmbiVax-CTM.
  • The vaccine is a reliable, accessible alternative in these regions, allowing immunization and longevity of immunity with the boosters against the Covid variants of concern.
  • Biolexis Private Limited (Biolexis) is an emerging biotech and vaccine company capable of developing and commercializing products for the Global markets.

JSR Life Sciences Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA

Retrieved on: 
Monday, May 2, 2022
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, JSR, Drug development, Organizational culture, Pathfinder, Immortalised cell line, LLC, Triangle Park (Quezon City), Crown Bioscience International, CGMP, Patient, LTD, Organization, KBI, GMP, Family, Therapy, Industry, Stelis, U.S. Navy Diving Manual, CDMO, Leadership, Health, Vaccine, RTP, Solution, CEO, Growth, Management, Fine chemical, Pharmaceutical industry

His innate commitment to quality and innovation is a natural fit for the JSR family and a significant win for Selexis and KBI partners and employees.

Key Points: 
  • His innate commitment to quality and innovation is a natural fit for the JSR family and a significant win for Selexis and KBI partners and employees.
  • Womack brings a consistent track record of successful leadership and life sciences experience to KBI and Selexis.
  • A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry.
  • JSR LSs global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.